Biliary Strictures Caused by Malignant Neoplasms Clinical Trial
Official title:
A Multi-Center, Single Arm, Prospective Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
| Verified date | August 2009 |
| Source | Boston Scientific Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a a prospective study of the WallFlex™ Biliary Partially-covered Stent designed to collect data to support regulatory clearance by the FDA in the United States and to determine the functionality of the WallFlex™ Biliary Partially Covered Stent as a Palliative treatment for malignant bile duct obstruction.
| Status | Completed |
| Enrollment | 70 |
| Est. completion date | May 2008 |
| Est. primary completion date | May 2008 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Age 18 years or older - Inoperable extrahepatic biliary obstruction by any malignant process - Indicated for metal stent placement for palliative treatment of biliary stricture(s) produced by malignant neoplasms - Willing and able to comply with the study procedures and provide written informed consent to participate in the study Exclusion Criteria: - Participation in another invesitgational study within 90 days prior to date of patient consent. - Strictures that cannot be dialated enough to pass the delivery system - Perforation of any duct within the biliary tree - Presence of any esophageal or duodenal stent - Patients for whom endoscopic procedures are contraindicated - Patients with known senesitivity to any components of the stent or delivery system - Patients with active hepatitis |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | ULB Erasme Hospital | Brussels | |
| France | Hopital Edouard Herriot | Lyon | Cedex 3 |
| Germany | EVK Krankenhaus der Universitat Dusseldorf | Dusseldorf | |
| India | Asian Institute of Gastroenterology | Hyderabaad | |
| Italy | Università Cattolica del Sacro Cuore | Rome | |
| Netherlands | Academisch Medisch Centrum Universiteit van Amsterdam | Amsterdam | AZ |
| Lead Sponsor | Collaborator |
|---|---|
| Boston Scientific Corporation |
Belgium, France, Germany, India, Italy, Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants With Absence of Recurrent Biliary Obstruction | Defined as absence of recurrent biliary obstruction defined as absence of biliary symptoms. Biliary symptoms, included, but were not limited to jaundice, itching, right upper quadrant abdominal pain, nausea, vomiting, fever, and dark urine. Symptom assessment occurred during the Screening/Baseline period and at all follow-up time points. | Up to 6 months post treatment or prior to death, whichever came first | |
| Secondary | Number of Adverse Events Related to the Device and/or Procedure | Number of adverse events (serious and non-serious) related to the device and/or procedure were collected following informed consent, treatment, and at all follow-up timepoints. | From time participant signs informed consent until time participant exits study (up to 6 months following stent placement) | |
| Secondary | Number of Participants With Technical Stent Placement Success | Technical stent placement success defined as the ability to deploy the stent in satisfactory position across the stricture | Initial stent placement procedure | |
| Secondary | Number of Participants With Occurrence of Re-intervention | A re-intervention is defined as any type of endoscopic, percutaneous, or surgical procedure to improve biliary drainage after insertion of the initial study stent. Re-intervention does not include a second WallFlex stent placement during the 7 days post initial placement as a second stent could have been placed due to misplacement or failure to cover the entire stricture. | Up to 6 months post-initial study treatment | |
| Secondary | Change in Biliary Obstruction Symptoms | Incidence of symptoms of biliary obstruction | up to 6 months post-initial study treatment | |
| Secondary | Time to Recurrent Biliary Obstruction | Biliary obstruction symptoms were collected at all follow-up visits post treatment and included but not limited to jaundice, itching, right upper quadrant abdominal pain, nausea, vomiting, fever, and dark urine. The time to recurrent biliary obstruction was recorded. | Up to 6 months | |
| Secondary | Change in Bilirubin | Bilirubin change at 1 month following stent placement as assessed against bilirubin at baseline. | 1 month following stent placement |